← Browse by Condition
Medical Condition
refractory b cell non hodgkin lymphoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1
NCT05801913 Phase 1
Recruiting
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
Enrollment
15 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT04637763 Phase 1
Recruiting
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Enrollment
72 pts
Location
United States, Austr...
Sponsor
Caribou Biosciences, Inc.